A placebo-controlled study of 2-day pre-treatment with fexofenadine in seasonal allergic rhinitis

Trial Identifier: LPS17180
Sponsor: Opella Healthcare Group SAS, a Sanofi Company
Start Date: January 2023
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
CANADA, Ontario Kingston, Ontario, CANADA, K7L 2V7